S.3187 - Food and Drug Administration Safety and Innovation Act112th Congress (2011-2012)
Refine your search
S.Amdt.2111 — 112th Congress (2011-2012)
||To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market.
||Sen. Bingaman, Jeff [D-NM] (Submitted 05/17/2012) (Proposed 05/24/2012)
||05/24/12 Amendment SA 2111, under the order of 5/23/12, not having achieved 60 votes in the affirmative, was not agreed to in Senate by Yea-Nay Vote. 28 - 67. Record Vote Number: 105.